Skip to content
HowShorted

Taysha Gene Therapies, Inc. short interest in 2022

In 2022, Taysha Gene Therapies, Inc.'s disclosed short interest ran from 7.87% of shares outstanding on 14 Jan 2022 to 2.19% on 30 Dec 2022, a change of -5.68 percentage points. The year's high was 9.46% on 15 Feb 2022 and its low 1.32% on 30 Nov 2022, averaging 4.37% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.50 days on 14 Jan 2022. Full history: Taysha Gene Therapies, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Taysha Gene Therapies, Inc. in 2022

2022 in figures

Start of year
7.87% (14 Jan 2022)
End of year
2.19% (30 Dec 2022)
Change
-5.68 pp
High
9.46% (15 Feb 2022)
Low
1.32% (30 Nov 2022)
Average
4.37%
Highest days to cover
27.50 (14 Jan 2022)
SEC filings marked
9

Every report in 2022

Taysha Gene Therapies, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20227.87%27.50
31 Jan 20228.61%15.14
15 Feb 20229.46%11.21
28 Feb 20228.83%12.73
15 Mar 20228.89%18.57
31 Mar 20229.25%16.6010-K filed, results (8-K)
29 Apr 20223.90%5.86
13 May 20224.59%6.94
31 May 20224.40%5.1410-Q filed, results (8-K)
15 Jun 20224.24%6.75
30 Jun 20223.11%2.31
15 Jul 20222.70%8.77
29 Jul 20222.41%9.67
15 Aug 20222.10%6.8610-Q filed, results (8-K)
31 Aug 20222.17%16.21
15 Sep 20222.28%11.00
30 Sep 20222.16%5.35
14 Oct 20222.34%10.02
31 Oct 20224.07%1.00results (8-K)
15 Nov 20222.15%1.0010-Q filed, results (8-K)
30 Nov 20221.32%1.23
15 Dec 20221.48%2.08
30 Dec 20222.19%1.98

See also: Taysha Gene Therapies, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.